MPP-Our Work

The MPP is a public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries, especially for HIV, hepatitis C and tuberculosis treatment. To date, we have secured licences for thirteen antiretrovirals, three hepatitis C direct-acting antivirals, one tuberculosis medicine and an HIV technology platform.

We have sublicensed to many product developers and generic manufacturers to develop and supply medicines in developing countries. Access our “Products licensed” page.

MPP in Numbers

9 patent holders with MPP signed agreements

17 million patient-years through MPP’s generic partners from January 2012 to December 2017

24 generic manufacturers and product developers sublicensed from the MPP

18 products licensed to the MPP

130+

130+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

553

553 million dollars saved, from January 2012 to December 2017

KPMG calculated savings of USD553 million and supply of 17 million patient-years of treatments through the MPP’s generic partners from January 2012 to December 2017. Read the report.

MPP-WHO forecasting collaboration:
the MPP and the World Health Organization (WHO) prepare joint forecasts on the use of antiretroviral medicines in developing countries. We work together to pool respective information and insights from our partners. Read our latest forecast analysis : Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025